Use of lactobacillus salivarius

Abstract

Lactobacillus salivarius is useful in the prophylaxis or treatment of undesirable inflammatory activity, especially gastrointestinal inflammatory activity such as inflammatory bowel disease or irritable bowel syndrome. The inflammatory activity may also be due to cancer. The Lactobacillus salivarius is of human origin isolated from resected and washed human gastrointestinal tract. One such strain is UCC 118 described in WO-A-9835014.

1 - 51 . (canceled)  
     
     
         52 . A method of treating or preventing inflammation or an inflammatory disease in a subject which comprises administering to the subject a preparation comprising a  Lactobacillus salivarius  strain of  Lactobacillus salivarius  wherein the  Lactobacillus salivarius  strain is isolated from resected and washed human gastrointestinal tract.  
     
     
         53 . The method of  claim 52  wherein the inflammation is gastrointestinal inflammation.  
     
     
         54 . The method of  claim 52 , wherein the inflammatory disease is selected from any one or more of inflammatory bowel disease, Crohn's disease, ulcerative colitis, irritable bowel syndrome, pouchitis, post infection colitis, diarrhoeal disease, and a systemic inflammatory disease.  
     
     
         55 . The method of  claim 54 , wherein the diarrhoeal disease is associated with Clostridium difficile.  
     
     
         56 . The method of  claim 54 , wherein the diarrhoeal disease is associated with Rotovirus.  
     
     
         57 . The method of  claim 54 , wherein the diarrhoeal disease is post infective diarrhoeal disease.  
     
     
         58 . The method of  claim 53 , wherein the inflammation is due to a cancer or an autoimmune disorder.  
     
     
         59 . The method of  claim 52 , wherein the systemic inflammatory disease is rheumatoid arthritis.  
     
     
         60 . The method of  claim 58 , wherein the cancer is gastrointestinal cancer.  
     
     
         61 . The method of  claim 52 , which further comprises administering to the subject another probiotic material.  
     
     
         62 . The method of  claim 52 , which further comprises administering to the subject a prebiotic material.  
     
     
         63 . The method of  claim 52 , wherein the preparation is a formulation comprising an ingestible carrier.  
     
     
         64 . The method of  claim 63 , wherein the ingestible carrier is a pharmaceutically acceptable carrier.  
     
     
         65 . The method of  claim 64 , wherein the formulation is a pharmaceutical formulation in the form of a tablet, a capsule, or a powder.  
     
     
         66 . The method of  claim 63 , wherein the ingestible carrier comprises a protein, a polypeptide, a peptide, or a combination thereof.  
     
     
         67 . The method of  claim 66 , wherein the protein, the polypeptide, or the peptide is rich in glutamine, glutamate, or both.  
     
     
         68 . The method of  claim 63 , wherein the ingestible carrier comprises a lipid, a carbohydrate, a vitamin, a mineral, a trace element, or a combination thereof.  
     
     
         69 . The method of  claim 63 , wherein the ingestible carrier is a food product.  
     
     
         70 . The method of  claim 69 , wherein the food product is selected from any one or more of acidified milk, yoghurt, a frozen yoghurt, a milk powder, a milk concentrate, a cheese spread, a dressing, and a beverage.  
     
     
         71 . The method of  claim 52 , wherein the  Lactobacillus salivarius  strain is present at more than 10 6  cfu per gram of preparation.  
     
     
         72 . The method of  claim 52 , wherein the preparation comprises an adjuvant, bacterial components, a drug, a biological compound, or a combination thereof.  
     
     
         73 . The method of  claim 52 , wherein the subject is a mammal.  
     
     
         74 . The method of  claim 73 , wherein the mammal is human.  
     
     
         75 . The method of  claim 52 , wherein the  Lactobacillus salivarius  strain is in the form of viable cells.  
     
     
         76 . The method of  claim 52 , wherein the  Lactobacillus salivarius  strain is in the form of non-viable cells.  
     
     
         77 . The method of  claim 52 , wherein the  Lactobacillus salivarius  strain inhibits a broad range of Gram positive and Gram negative microorganisms.  
     
     
         78 . The method of  claim 52 , wherein the  Lactobacillus salivarius  strain secretes a product having anti-microbial activity into a cell-free supernatant, said activity being produced only by growing cells and being destroyed by proteinase K, pronase E, or both.  
     
     
         79 . The method of  claim 52 , wherein the  Lactobacillus salivarius  strain is  Lactobacillus salivarius  subspecies  salivarius.    
     
     
         80 . The method of  claim 52 , wherein the  Lactobacillus salivarius  strain is UCC118 [NCIMB 40829] or a mutant or variant thereof.  
     
     
         81 . The method of  claim 52 , wherein the  Lactobacillus salivarius  strain is a genetically modified mutant strain.  
     
     
         82 . The method of  claim 52 , wherein the  Lactobacillus salivarius  strain is a naturally occurring variant of  Lactobacillus salivarius.    
     
     
         83 . A method of treating or preventing inflammation or an inflammatory disease in a subject comprising administering to the subject a preparation comprising a  Lactobacillus salivarius  strain of  Lactobacillus salivarius  wherein the  Lactobacillus salivarius  is characterised by changing an immunological marker when introduced into a system comprising cells which interact with the immune system and cells of the subject.  
     
     
         84 . The method  claim 83  wherein the strain of  Lactobacillus salivarius  is isolated from resected and washed human gastrointestinal tract.  
     
     
         85 . The method of  claim 83  wherein the cells which interact with the immune system are epithelial cells.  
     
     
         86 . The method of  claim 83 , wherein the immunological marker is a cytokine.  
     
     
         87 . The method of  claim 86 , wherein the cykotine is TNFα.  
     
     
         88 . The method of  claim 83 , wherein the cells which interact with the immune system and the immune system cells are of matched origin.  
     
     
         89 . The method of  claim 83 , wherein the cells which interact with the immune system are of gastrointestinal, respiratory, or genitourinary origin.  
     
     
         90 . The method of  claim 83 , wherein the cells of the immune system are of gastrointestinal, respiratory, or genitourinary origin.  
     
     
         91 . A method of treating or preventing inflammation or an inflammatory disease in a subject which comprises administering to the subject a preparation comprising a strain of  Lactobacillus salivarius  UCC118 [NCIMB 40829] or a mutant or variant thereof.  
     
     
         92 . The method of  claim 91 , wherein the  Lactobacillus salivarius  strain is a genetically modified mutant strain.  
     
     
         93 . The method of  claim 91 , wherein the  Lactobacillus salivarius  strain is a naturally occurring variant of Lactobacillus salivarius.  
     
     
         94 . The method of  claim 91 , wherein the  Lactobacillus salivarius  strain is in the form of viable cells.  
     
     
         95 . The method of  claim 91 , wherein the  Lactobacillus salivarius  strain is in the form of non-viable cells.  
     
     
         96 . A method of treating or preventing cancer in a subject which comprises administering to the subject a  Lactobacillus salivarius  strain of  Lactobacillus salivarius  or a mutant or variant thereof.